Company intelligence / Profile preview

Metabolic Disorders

Melbourne, Victoria, Australia

Ownership: Private
Development stage: Other

Overview

Metabolic Pharmaceuticals was an Australian biotechnology company focused on developing therapies for metabolic diseases and neuropathic pain. The company's lead candidate, AOD9604, was a peptide derived from human growth hormone intended for the treatment of obesity, though it failed to meet primary endpoints in Phase 2b clinical trials. Following the clinical setbacks of its primary programs, the company underwent significant restructuring and eventually transitioned its business focus away from drug development. It is no longer an active entity in the life sciences sector under its original form.

Therapeutic areas: RheumatologyNeurologyEndocrinology
Modalities: PeptidesSmall molecule
Industry: Biotech

Beyond the preview

Go deeper on Metabolic Disorders.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Metabolic Disorders.

Explore the full profile